Miguel Regueiro

8.5k total citations · 1 hit paper
184 papers, 3.4k citations indexed

About

Miguel Regueiro is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Miguel Regueiro has authored 184 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Genetics, 91 papers in Epidemiology and 71 papers in Surgery. Recurrent topics in Miguel Regueiro's work include Inflammatory Bowel Disease (137 papers), Microscopic Colitis (82 papers) and Eosinophilic Esophagitis (24 papers). Miguel Regueiro is often cited by papers focused on Inflammatory Bowel Disease (137 papers), Microscopic Colitis (82 papers) and Eosinophilic Esophagitis (24 papers). Miguel Regueiro collaborates with scholars based in United States, Belgium and Germany. Miguel Regueiro's co-authors include Bruce E. Sands, Edward V. Loftus, Kim L. Isaacs, Gary R. Lichtenstein, Lauren B. Gerson, Scott E. Plevy, Leonard Baidoo, Ewen M. Harrison, Wolfgang H. Schraut and Kevin E. Kip and has published in prestigious journals such as Journal of Clinical Investigation, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Miguel Regueiro

162 papers receiving 3.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ACG Clinical Guideline: Management of Crohn's Disease in Adults

2018 903 citations Miguel Regueiro, Bruce E. Sands et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miguel Regueiro United States	25	2.4k	1.8k	1.3k	416	314	184	3.4k
Talat Bessissow Canada	29	2.0k 0.8×	1.8k 0.9×	1.1k 0.8×	389 0.9×	361 1.1×	204	3.0k
Mariangela Allocca Italy	33	2.0k 0.8×	1.6k 0.9×	1.1k 0.8×	453 1.1×	320 1.0×	177	3.3k
Miguel Regueiro United States	36	3.0k 1.2×	2.4k 1.3×	1.3k 1.0×	492 1.2×	427 1.4×	174	4.2k
Fabiana Castiglione Italy	33	2.3k 1.0×	1.9k 1.0×	1.3k 1.0×	426 1.0×	438 1.4×	144	3.6k
Vipul Jairath Canada	31	2.2k 0.9×	1.6k 0.8×	1.1k 0.8×	515 1.2×	214 0.7×	192	3.0k
Henit Yanai Israel	28	1.8k 0.8×	1.3k 0.7×	923 0.7×	600 1.4×	436 1.4×	125	2.6k
Nilesh Chande Canada	30	1.8k 0.7×	1.6k 0.9×	872 0.7×	308 0.7×	340 1.1×	95	3.2k
Parakkal Deepak United States	27	1.4k 0.6×	1.1k 0.6×	832 0.6×	397 1.0×	273 0.9×	209	2.5k
Konstantinos Κarmiris Greece	23	2.1k 0.8×	1.7k 0.9×	753 0.6×	708 1.7×	231 0.7×	60	3.2k
K Gecse Netherlands	34	3.1k 1.3×	2.2k 1.2×	1.9k 1.5×	594 1.4×	596 1.9×	174	4.6k

Countries citing papers authored by Miguel Regueiro

Since Specialization

Citations

This map shows the geographic impact of Miguel Regueiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel Regueiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel Regueiro more than expected).

Fields of papers citing papers by Miguel Regueiro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel Regueiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel Regueiro. The network helps show where Miguel Regueiro may publish in the future.

Co-authorship network of co-authors of Miguel Regueiro

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel Regueiro. A scholar is included among the top collaborators of Miguel Regueiro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel Regueiro. Miguel Regueiro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kochhar, Gursimran, et al.. (2025). Natural History, Treatment Persistence and Predictors of Treatment Failure in Patients With Ulcerative Colitis on 5-Aminosalicylic Acid: A US Population-Level Cohort Study. Inflammatory Bowel Diseases. 31(11). 3069–3076.

Vermeire, Séverine, David T. Rubin, Laurent Peyrin-Biroulet, et al.. (2025). Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterology. 12(1). e001516–e001516. 6 indexed citations

Shehab, Mohammad, Péter L. Lakatos, Matthieu Allez, et al.. (2025). Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn’s Disease: A Systematic Review and Network Meta-Analysis. Inflammatory Bowel Diseases. 32(1). 25–38.

Vermeire, Séverine, Bruce E. Sands, G. D’Haens, et al.. (2025). DOP005 Long-term efficacy and safety of mirikizumab treatment for Crohn’s Disease: Results from the VIVID-2 open-label extension study. Journal of Crohn s and Colitis. 19(Supplement_1). i91–i93. 2 indexed citations

Joseph, Abel, Salam Bachour, Ravi S. Shah, et al.. (2024). Postoperative Crohn’s Disease Recurrence Risk and Optimal Biologic Timing After Temporary Diversion Following Ileocolic Resection. Inflammatory Bowel Diseases. 31(3). 686–695.

Regueiro, Miguel, Monika Fischer, Peter Bossuyt, et al.. (2024). Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn’s Disease in the Phase 2 AMAG Study. Inflammatory Bowel Diseases. 31(2). 432–441. 4 indexed citations

Cooper, Gregory S., et al.. (2024). The Natural History of Inflammatory Bowel Disease in Adults With Common Variable Immunodeficiency: A Case Series From a Single US Tertiary Care Center. Crohn s & Colitis 360. 7(1). otae062–otae062. 1 indexed citations

Regueiro, Miguel, Britta Siegmund, Sara N. Horst, et al.. (2024). Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. Inflammatory Bowel Diseases. 31(4). 1010–1017.

Colombel, Jean‐Frédéric, Tadakazu Hisamatsu, Raja Atreya, et al.. (2024). Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy. Clinical Gastroenterology and Hepatology. 22(8). 1668–1677. 6 indexed citations

10.

Vermeire, Séverine, Laurent Peyrin‐Biroulet, Julián Panés, et al.. (2023). P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials. Journal of Crohn s and Colitis. 17(Supplement_1). i619–i620. 9 indexed citations

11.

Shah, Ravi S., Salam Bachour, Abel Joseph, et al.. (2023). Mo1745 HISTOLOGIC ACTIVITY DESPITE ENDOSCOPIC REMISSION PREDICTS CROHN'S DISEASE RECURRENCE FOLLOWING ILEOCOLONIC RESECTION. Gastroenterology. 164(6). S–890. 1 indexed citations

12.

Colombel, Jean‐Frédéric, Tadakazu Hisamatsu, Francesca Bresso, et al.. (2023). Tu1716 UPADACITINIB THERAPY REDUCES CROHN'S DISEASE SYMPTOMS WITHIN THE FIRST WEEK OF INDUCTION THERAPY. Gastroenterology. 164(6). S–1091. 1 indexed citations

13.

Rubin, David T., et al.. (2023). 963 BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS. Gastroenterology. 164(6). S–213. 2 indexed citations

14.

Colombel, J F, Tadakazu Hisamatsu, Francesca Bresso, et al.. (2023). DOP38 Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy. Journal of Crohn s and Colitis. 17(Supplement_1). i102–i103. 4 indexed citations

15.

Danese, Silvio, Remo Panaccione, María T. Abreu, et al.. (2023). Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. Journal of Crohn s and Colitis. 18(2). 264–274. 26 indexed citations

16.

Kochhar, Gursimran, Aakash Desai, Francis A. Farraye, et al.. (2023). Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort study. Alimentary Pharmacology & Therapeutics. 58(3). 297–308. 16 indexed citations

17.

Shah, Ravi S., Salam Bachour, Abel Joseph, et al.. (2023). Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s Disease. Clinical Gastroenterology and Hepatology. 22(4). 847–857.e12. 5 indexed citations

18.

Uttam, Shikhar, Jana G. Hashash, David G. Binion, et al.. (2019). Three-Dimensional Nanoscale Nuclear Architecture Mapping of Rectal Biopsies Detects Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. Cancer Prevention Research. 12(8). 527–538. 9 indexed citations

19.

Pai, Rish K., Douglas J. Hartman, Claudia Ramos Rivers, et al.. (2019). Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 18(11). 2510–2517.e5. 49 indexed citations

20.

Martínez, Walter, et al.. (2000). Pelagra e infección por VIH. Actas Dermo-Sifiliográficas. 91(4). 157–162. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact